<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Research in 2021 | ARSACS</title>
	<atom:link href="https://arsacs.com/fr/category/research-in-2021/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com/fr</link>
	<description>Research That Heals</description>
	<lastBuildDate>Mon, 16 Mar 2026 22:14:07 +0000</lastBuildDate>
	<language>fr-CA</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>Research in 2021 | ARSACS</title>
	<link>https://arsacs.com/fr</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>&#8220;Danio Rerio as a model to reveal new insight of retinal defects in ARSACS&#8221;- Dr. Valentina Naef</title>
		<link>https://arsacs.com/fr/danio-rerio-as-a-model-to-reveal-new-insight-of-retinal-defects-in-arsacs-dr-valentina-naef-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 07 Mar 2022 20:17:44 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=16812</guid>

					<description><![CDATA[The ataxia of Charlevoix-Saguenay is a rare neurodevelopmental condition associated with structural retinal abnormalities. Mouse models cannot help to clarify this feature.&#160; This project will investigate retinal defects driven by the loss of&#160;SACS&#160;using a new null-sacs&#160;zebrafish line that replicates main features of ARSACS. Thanks to this small but new powerful vertebrate model,&#160;we will try to [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">The ataxia of Charlevoix-Saguenay is a rare neurodevelopmental condition associated with structural retinal abnormalities. Mouse models cannot help to clarify this feature.&nbsp; This project will investigate retinal defects driven by the loss of&nbsp;<em>SACS</em>&nbsp;using a new null-<em>sacs&nbsp;</em>zebrafish line that replicates main features of ARSACS. Thanks to this small but new powerful vertebrate model,&nbsp;we will try to characterize and define the nature of the retinal findings seen in ARSACS patients. Retinal studies in ARSACS could represent an attractive target to investigate the consequences of sacsin depletion,&nbsp; to develop potential therapies, and to reveal new information to halt disease progression.</p>



<p class="wp-block-paragraph">Project funded by the <a href="http://www.arsacsodv.it/" target="_blank" rel="noopener">Organizzazione di volontariato (ODV)&nbsp;</a>with the support from the&nbsp;Fondazione&nbsp;Telethon.</p>



<p class="wp-block-paragraph">Grant:  50.000€</p>



<p class="wp-block-paragraph">Durée : un an </p>



<p class="wp-block-paragraph">Contact : </p>



<figure class="wp-block-image size-full"><img decoding="async" width="189" height="200" src="https://arsacs.com/wp-content/uploads/2022/03/valentina-naef.jpg" alt="" class="wp-image-16815"/></figure>



<p class="wp-block-paragraph">Dr. Valentina Naef </p>



<p class="wp-block-paragraph">Stella Maris Foundation (IRCCS) Calambrone, Italy</p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Corticospinal  tract microstructural integrity and its correlation with clinical and  molecular biomarkers: a profilometry MRI study to identify in-vivo  biomarkers of disease severity  in ARSACS&#8221;- Dr. Sirio Cocozza</title>
		<link>https://arsacs.com/fr/corticospinal-tract-microstructural-integrity-and-its-correlation-with-clinical-and-molecular-biomarkers-a-profilometry-mri-study-to-identify-in-vivo-biomarkers-of-disease-severity-in-arsacs/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Mon, 07 Mar 2022 15:30:05 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=16798</guid>

					<description><![CDATA[Patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) encounter symptoms that affect their walking ability. Among these, they show abnormal tensing of the muscles (spasticity), which partly derives from the disruption of a bundle of fibers responsible for voluntary motion (the corticospinal tract). Damage to the corticospinal tract has been sporadically reported in ARSACS, [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">Patients with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) encounter symptoms that affect their walking ability. Among these, they show abnormal tensing of the muscles (spasticity), which partly derives from the disruption of a bundle of fibers responsible for voluntary motion (the corticospinal tract). Damage to the corticospinal tract has been sporadically reported in ARSACS, but we do not know which portion of the fibers is damaged nor if higher degree of damage corresponds to worse symptoms. In this study we will assess the integrity of the corticospinal tract using a novel approach, based on the examination of proteins presents in peripheral blood and Magnetic Resonance Imaging of the brain. We will use data from a large group of ARSACS patients, available from the PROSPAX project, a multi-center European study that includes clinical, molecular and imaging data. We will reconstructs for each subject the corticospinal tract, investigating whether alterations at the microstructural level of the fibers that constitute this bundle are associated to markers of fiber damage measured in peripheral blood and to the degree of clinical impairment. If, as we hypothesize, spasticity will be associated to specific microstructural abnormalities of the corticospinal tract, which, in turn, will be associated to a marker of fiber damage measurable in the blood, we will have identified one (or more) biomarkers that can be obtained from a non-invasive brain MRI and that can be used not only to monitor brain damage and disease progression but, in the future, to monitor response to therapies.</p>



<p class="wp-block-paragraph">Project funded by the <a href="http://www.arsacsodv.it/" target="_blank" rel="noopener">Organizzazione di volontariato (ODV)&nbsp;</a>with the support from the&nbsp;Fondazione&nbsp;Telethon.</p>



<p class="wp-block-paragraph">Grant:  30.450€</p>



<p class="wp-block-paragraph">Durée : un an </p>



<p class="wp-block-paragraph">Contact : </p>



<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2022/03/sirio-cocozza.jpg" alt="" class="wp-image-16800" width="130" height="130" srcset="https://arsacs.com/wp-content/uploads/2022/03/sirio-cocozza.jpg 200w, https://arsacs.com/wp-content/uploads/2022/03/sirio-cocozza-150x150.jpg 150w" sizes="(max-width: 130px) 100vw, 130px" /></figure>



<p class="wp-block-paragraph">Dr. Sirio Cocozza</p>



<p class="wp-block-paragraph">University of Naples Federico 11 </p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Charting the neurodevelopmental stage of ARSACS (NeurodevARSACS): A cross-species longitudinal characterization of the early molecular changes in the brain, CSF and blood” &#8211; Drs. Justin Wolter, Matthis Synofzik &#038; David Mengel</title>
		<link>https://arsacs.com/fr/charting-the-neurodevelopmental-stage-of-arsacs-neurodevarsacs-a-cross-species-longitudinal-characterization-of-the-early-molecular-changes-in-the-brain-csf-and-blood-drs-just/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 23:03:08 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15917</guid>

					<description><![CDATA[It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early molecular and cellular changes that precede the loss of neurons in ARSACS, let alone biomarkers which would allow [...]]]></description>
										<content:encoded><![CDATA[<p>It is well established in neurodegenerative diseases that early therapeutic intervention - ideally before neurodegenerative cascades begin to breakdown neuronal function - is key to the success of disease-modifying therapies. Yet we do not understand the early molecular and cellular changes that precede the loss of neurons in ARSACS, let alone biomarkers which would allow us to track the earliest stages of the disease. Understanding the early changes in ARSACS will clarify fundamental molecular deficiencies, and motivate preemptive therapeutic strategies aimed at delaying, or possibly preventing, the progression of this disease.</p>
<p>The goals of this project are to generate a cross-species map of the developmental trajectory of ARSACS through the lens of molecular and cellular deficits in the ARSACS mouse model, and readily accessible fluid biomarkers in mice and human patients. This paired longitudinal study design will allow us to mechanistically anchor readily available fluid biomarkers with early cellular abnormalities in the ARSACS brain.</p>
<p>Grant: $80,000 for the first year&nbsp;</p>
<p style="text-align: left;">Duration: 2 year project&nbsp;</p>
<p>Contact :&nbsp;</p>
<p style="padding-left: 40px; text-align: left;"><img loading="lazy" decoding="async" class="wp-image-11785 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Matthis_Synofzik.jpg" alt="" width="135" height="135">Dr. Matthis Synofzik&nbsp;</p>
<p style="text-align: left; padding-left: 40px;">&nbsp;Hertie- Institute for Clinical Brain Research<br>&nbsp;Hoppe-Seyler-Strasse 3, 72076 Tubingen, Germany&nbsp;<br>&nbsp;email: matthis.synofzik@uni-tuebingen.de</p>
<p style="text-align: left;">
</p><p style="padding-left: 240px; text-align: left;">
</p><p style="padding-left: 40px; text-align: left;"><img loading="lazy" decoding="async" class="wp-image-16104 alignleft" src="https://arsacs.com/wp-content/uploads/2021/12/David_Mengel-HF-cropped-1-225x300.jpg" alt="" width="130" height="173"></p>
<p style="padding-left: 200px;">Dr. David Mengel&nbsp;</p>
<p style="padding-left: 200px;">&nbsp;Hertie- Institute for Clinical Brain Research<br>&nbsp;Hoppe-Seyler-Strasse 3, 72076 Tubingen, Germany&nbsp;<br>&nbsp;email: <a class="rABsFf RffVmb AL18ce" href="mailto:david.mengel@uni-tuebingen.de" target="_blank" rel="noopener" data-tooltip-position="top" data-tooltip="From your Google Contacts">david.mengel@uni-tuebingen.de</a></p>
<p style="padding-left: 240px;">
</p><p style="text-align: left; padding-left: 40px;"><img loading="lazy" decoding="async" class="wp-image-11490 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/Justin-Wolter1-e1604075278293.jpg" alt="" width="115" height="173"></p>
<p></p>
<p style="text-align: left; padding-left: 200px;"><span style="font-size: revert;">Dr Justin Wolter&nbsp;</span></p>
<p style="text-align: left; padding-left: 200px;">Mary Ellen Jones Building CB#7250<br>116 Manning Dr., Chapel Hill, NC, US 27599<br>&nbsp;email: justin_wolter@med.unc.edu</p>
<p style="padding-left: 40px;">
</p><p style="text-align: left; padding-left: 240px;">
</p><p style="text-align: left;">
</p>
<p style="text-align: center;">
</p><p style="text-align: center;">
</p><p style="text-align: center;"></p>


<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Unravelling defective Purkinje cell-postsynaptic signalling in ARSACS” &#8211; Dr. Francesca Maltecca</title>
		<link>https://arsacs.com/fr/unravelling-defective-purkinje-cell-postsynaptic-signalling-in-arsacs-dr-francesca-maltecca-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:43:06 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15574</guid>

					<description><![CDATA[We discovered that sacsin specifically localizes at the post-synaptic density of the cerebellum, where it controls key proteins involved in synapse organization and trans-synaptic signaling, required for tuning the firing properties of Purkinje cells. The project aims at defining how defects in this pathway can influence Purkinje cell-spine functionality and firing, contributing to the motor [...]]]></description>
										<content:encoded><![CDATA[<p class="PANormalLevelIA" style="text-align: justify;"><span lang="EN-US">We discovered that sacsin specifically localizes at the post-synaptic density of the cerebellum, where it controls key proteins involved in synapse organization and trans-synaptic signaling, required for tuning the firing properties of Purkinje cells. The project aims at defining how defects in this pathway can influence Purkinje cell-spine functionality and firing, contributing to the motor coordination defects observed in ARSACS. This study may identify new valuable targets for therapeutic intervention.</span></p>
<p>Grant: $80,000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p style="text-align: left;"><img loading="lazy" decoding="async" class="size-full wp-image-11103 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrFrancescaMaltecca-150x150-2.jpg" alt="" width="150" height="150"></p>
<p>Dre Francesca Maltecca</p>
<p>Ospedale San Raffaele</p>
<p>Via Olgettina 58,20132, Milan, Italy&nbsp;&nbsp;</p>
<p>email: maltecca.francesca@hsr.it</p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Structural Determination and Super Resolution Imaging of Sacsin” &#8211; Dr. Walid Houry</title>
		<link>https://arsacs.com/fr/structural-determination-and-super-resolution-imaging-of-sacsin-dr-walid-houry-3/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:42:14 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15566</guid>

					<description><![CDATA[The SACS protein, whose mutation results in ARSACS, is among the largest proteins in human cells (4579 residues), which hindered the determination of its structure and made basic biochemical experiments problematic. In the proposed project, we aim to use novel tagging approaches to allow SACS purification in its native state for structural determination, and also [...]]]></description>
										<content:encoded><![CDATA[<p>The SACS protein, whose mutation results in ARSACS, is among the largest proteins in human cells (4579 residues), which hindered the determination of its structure and made basic biochemical experiments problematic. In the proposed project, we aim to use novel tagging approaches to allow SACS purification in its native state for structural determination, and also for its super-resolution localization in fixed and live cells.</p>
<p>Grant: $80,000</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="alignleft size-full wp-image-6572" src="https://arsacs.com/wp-content/uploads/2021/02/Walid_Houry_University_Toronto-e1606423339816.jpg" alt="" width="127" height="150">Dr. Walid A. Houry, Department of Biochemistry</p>
<p>Faculté de médecine Temerty de l'Université de Toronto<br>661 University Avenue,MaRS Centre, West Tower, Room 1612</p>
<p>Toronto, ON, Canada M5G 1M1</p>
<p>email: walid.houry@utoronto.ca</p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Preclinical studies in the Sacs KO mouse model of ARSACS”- Dr. Stefan Strack</title>
		<link>https://arsacs.com/fr/preclinical-studies-in-the-sacs-ko-mouse-model-of-arsacs-dr-stefan-strack-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:41:25 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15578</guid>

					<description><![CDATA[The Strack team at the University of Iowa plans to continue with preclinical studies to prevent or reverse ARSACS symptoms in the SACS knock-out mouse model. Specifically, they are hoping to improve mitochondrial function via gene therapy and electromagnetic fields. Grant : $80,000 Duration : one year&#160; Contact :&#160; &#160;Dr.Stefan Strack, Department Neurosciences @Pharmacology University [...]]]></description>
										<content:encoded><![CDATA[<p>The Strack team at the University of Iowa plans to continue with preclinical studies to prevent or reverse ARSACS symptoms in the SACS knock-out mouse model. Specifically, they are hoping to improve mitochondrial function via gene therapy and electromagnetic fields.</p>
<p class="m_-2151711370727717155MsoListParagraph">Grant : $80,000</p>
<p>Durée : un an&nbsp;</p>
<p>Contact :&nbsp;</p>
<p>&nbsp;<img loading="lazy" decoding="async" class="wp-image-10779 alignleft" src="https://arsacs.com/wp-content/uploads/2021/02/DrStefanStrack.jpg" alt="" width="92" height="137" srcset="https://arsacs.com/wp-content/uploads/2021/02/DrStefanStrack.jpg 200w, https://arsacs.com/wp-content/uploads/2021/02/DrStefanStrack-133x200.jpg 133w" sizes="(max-width: 92px) 100vw, 92px" /><span style="font-size: revert;">Dr.Stefan Strack, Department Neurosciences @Pharmacology</span></p>
<p style="text-align: left;"><span style="font-size: revert;">Faculté de médecine Carver de l'Université de l'Iowa</span></p>
<p style="text-align: left;">2-452 BSB, 51 Newton Rd., Iowa City, IA 52242<br>email : Stefan-strack@uiowa.edu</p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Évaluer l&#8217;efficacité d&#8217;un programme de réadaptation à domicile visant l&#8217;amélioration des atteintes motrices, de l&#8217;équilibre, de la mobilité, des chutes et des activités courantes chez les personnes atteintes d&#8217;ARSACS”  &#8211; Dre Elise Duchesne</title>
		<link>https://arsacs.com/fr/evaluer-lefficacite-dun-programme-de-readaptation-a-domicile-visant-lamelioration-des-atteintes-motrices-de-lequilibre-de-la-mobilite-des-chutes-et-des-activites-courantes-chez-les-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:37:51 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15567</guid>

					<description><![CDATA[&#160; L’ataxie récessive spastique de Charlevoix-Saguenay (ARSACS) est une maladie incurable caractérisée par plusieurs déficiences motrices progressives apparaissant dès l’enfance. Bien que les atteintes soient majeures, entraînant de grandes difficultés à marcher et un nombre élevé de chutes, il existe peu de données probantes pour guider les interventions de réadaptation. Suite à la réalisation d’un [...]]]></description>
										<content:encoded><![CDATA[<p><em>&nbsp;</em></p>
<p>L’ataxie récessive spastique de Charlevoix-Saguenay (ARSACS) est une maladie incurable caractérisée par plusieurs déficiences motrices progressives apparaissant dès l’enfance. Bien que les atteintes soient majeures, entraînant de grandes difficultés à marcher et un nombre élevé de chutes, il existe peu de données probantes pour guider les interventions de réadaptation. Suite à la réalisation d’un projet pilote où 10 personnes atteintes d’ARSCS ont suivi un programme d’entraînement supervisé de groupe pendant 8 semaines, l’équipe clinique et les personnes atteintes ont souligné la nécessité de compléter cette offre de services par un programme à domicile pour répondre à certains enjeux identifiés tels que la disponibilité des personnes atteintes et du transport adapté pour leur permettre de participer à un programme de jour et la distance à parcourir/temps requis pour se rendre au centre de réadaptation. L’objectif de ce projet est d’évaluer les effets de PACE, un programme d’activités physiques à domicile adapté aux capacités fonctionnelles de la population ARSACS, sur les atteintes motrices, l’équilibre, la mobilité, les chutes et les activités courantes en comparaison des soins habituels.</p>
<p></p>
<p>Grant: $79,138</p>
<p>Durée : un an</p>
<p>Contact :</p>
<p><img loading="lazy" decoding="async" class="wp-image-15569 alignleft" src="https://arsacs.com/wp-content/uploads/2021/10/Elise-Duchesne-logos-168x300.jpeg" alt="" width="171" height="305"></p>


<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Dre Elise Duchesne</p>



<p class="wp-block-paragraph">Professeure agrégée , Unité d'enseignement en physiothérapie&nbsp;<br>Université du Québec à Chicoutimi&nbsp;</p>



<p class="wp-block-paragraph">555 Boulevard de l'Université , Chicoutimi (Québec) G7H 2B1</p>



<p class="wp-block-paragraph">email: elise1_duchesne@uqac.ca</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Is ARSACS a Tauopathy?&#8221;- Dr. Paul Chapple</title>
		<link>https://arsacs.com/fr/is-arsacs-a-tauopathy-dr-paul-chapple-3-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:36:58 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15819</guid>

					<description><![CDATA[This is the continuation of the project. More specific details to come.&#160;&#160; As an indication of the research, following is the description of last year work.&#160; Currently we are looking carefully at sacsin’s interaction with cytoskeletal proteins and defining the molecular mechanisms by which sacsin’s loss disrupts cytoskeletal function. This includes research examining a link [...]]]></description>
										<content:encoded><![CDATA[<p class="wp-block-paragraph">This is the continuation of the project. More specific details to come.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">As an indication of the research, following is the description of last year work.&nbsp;</p>



<p class="wp-block-paragraph">Currently we are looking carefully at sacsin’s interaction with cytoskeletal proteins and defining the molecular mechanisms by which sacsin’s loss disrupts cytoskeletal function. This includes research examining a link between cytoskeletal disruption, caused by loss of sacsin, and impaired formation of structures called focal adhesions that are important for cell movement. We are also looking at links between ARSACS and other neuronal diseases where cytoskeletal dysfunction is a feature, including Alzheimer’s disease. One of the key challenges that we wish to solve is understanding how all of the different problems identified in cells that do not have sacsin are integrated together. If we fully understand the ‘hierarch of events’ in the molecular pathology of cells that lack sacsin it will potentially facilitate the development of treatments for ARSACS.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Duration:  3rd year of a 3 year project </p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Grant: $56,906</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Contact : </p>



<figure class="wp-block-image alignleft"><img decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/DrPaulChapple.jpg" alt="Dr. Paul Chapple" class="wp-image-274"/></figure>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph">Dr.Paul Chapple, Professor of Molecular Cell Biology<br>Centre for Endocrinology Barts and The London, Queen Mary’s School of Medicine and Dentistry </p>



<p class="wp-block-paragraph">1st Floor North , John Vane Science Building, </p>



<p class="wp-block-paragraph">Charterhouse Square, London, EC1M 6BQ</p>



<p class="wp-block-paragraph">email:&nbsp;<a href="mailto:j.p.chapple@qmul.ac.uk">j.p.chapple@qmul.ac.uk</a></p>



<p class="has-text-align-left wp-block-paragraph"> </p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>“Exploring the role of genetic and epigenetic modifiers in modifiers in ARSACS” &#8211; Dr. Daniele Galatolo</title>
		<link>https://arsacs.com/fr/exploring-the-role-of-genetic-and-epigenetic-modifiers-in-modifiers-in-arsacs-dr-daniele-galatolo-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:35:26 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15590</guid>

					<description><![CDATA[  The overall aim of this research is to identify the potential co-occurrence of genomic variants beyond mutations in the SACS gene and the epigenetic effects that might explain the different phenotype severity existing among ARSACS patients. Grant: $52,000 Duration : one year Contact: Dr. Daniele Galatolo Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit [...]]]></description>
										<content:encoded><![CDATA[<em> </em>

The overall aim of this research is to identify the potential co-occurrence of genomic variants beyond mutations in the <em>SACS</em> gene and the epigenetic effects that might explain the different phenotype severity existing among ARSACS patients.

Grant: $52,000

Duration : one year

Contact:

<img loading="lazy" decoding="async" class="wp-image-15770 alignleft" src="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg" alt="" width="155" height="231" srcset="https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo-201x300.jpg 201w, https://arsacs.com/wp-content/uploads/2021/10/Daniele-Galatolo-photo.jpg 408w" sizes="(max-width: 155px) 100vw, 155px" />

Dr. Daniele Galatolo

Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit

IRCCS Stella Maris Foundation

via dei Giacinti 2,

56128 Calambrone (Pisa) - Italy

email : daniele.galatolo@fsm.unipi.it]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>&#8220;Therapeutic Approaches for ARSACS&#8221;- Drs. Benoit Gentil and Heather Durham</title>
		<link>https://arsacs.com/fr/therapeutic-approaches-for-arsacs-drs-benoit-gentil-andheather-durham/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 29 Oct 2021 19:29:30 +0000</pubDate>
				<category><![CDATA[Research in 2021]]></category>
		<guid ispermalink="false">https://arsacs.com/?p=15581</guid>

					<description><![CDATA[ARSACS is characterised by the lack of sacsin expression and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies. Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors and, because of the chaperone function of sacsin, to investigate the potential of [...]]]></description>
										<content:encoded><![CDATA[<p>ARSACS is characterised by the lack of sacsin expression and the formation of intermediate filaments bundles in neurons and fibroblasts derived from skin biopsies.<em> </em>Our strategy over the last years has been aimed at developing a replacement therapy, by peptide and/or gene vectors and, because of the chaperone function of sacsin, to investigate the potential of alternative therapies already in development in our laboratory to promote protein chaperoning. We have defined minimal domains necessary for the replacement therapy and identified that HDAC inhibitors have a strong therapeutic potential. Our laboratory is moving forward the development of a gene therapy and focused on the  Development of peptide and gene therapies. We have generated a AAV9 carrying a combination of sacsin domains and generated peptides derived from sacsin domains and will obtain proof of principle of efficiency. Our lab is also working on finding other therapeutic strategies and we are assessing the therapeutic potential of brain permeant HDAC inhibitors for ARSACS<strong>.</strong> We will examine the role of different HDACs inhibitors in resorbing intermediate filaments bundles.</p>
<p>Grant: $80,000</p>
<p>Durée : un an</p>
<p>Contacts<br /><img loading="lazy" decoding="async" class="alignleft size-thumbnail wp-image-3643" src="https://arsacs.com/wp-content/uploads/2021/02/Durham_Benoit_Nov_2017-150x150-2.jpg" alt="" width="150" height="150" />Le Dr Benoit Gentil  et le Dr Heather Durham</p>
<p><span style="font-size: revert;">Département de kinésiologie et d'éducation physique, Université McGill </span></p>
<p>475 Pine Avenue West,   room 210,  Montreal (Québec)  H2W 1S4</p>
<p>email: heather.durham@mcgill.ca, <span style="font-size: revert;"> benoit.gentil@mcgill.ca</span></p>


<p class="wp-block-paragraph"></p>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>